You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
哈藥股份(600664.SH)2019年淨利預降78%到90%
格隆匯 01-21 16:06

格隆匯1月21日丨哈藥股份(600664.SH)發佈2019年年度業績預告,預計2019年度實現歸屬於上市公司股東的淨利潤與上年同期相比,將減少2.7億元到3.1億元,同比減少78%到90%。歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期相比,將減少2.55億元到2.95億元,同比減少104%到121%。

預告期內,公司醫藥工業板塊因國家2019版醫保目錄調整、國家重點監控目錄的公佈等行業政策影響,公司前列地爾注射液等產品的銷量下降;因公司仿製藥一致性評價工作推進較慢,公司未獲得帶量採購政策紅利,部分市場受到其他公司已過評產品的衝擊;公司原有醫藥零售終端以單體藥店或小型連鎖為主,與醫藥零售行業不斷向頭部連鎖聚集的發展態勢不符,使得公司部分OTC及保健品的銷量下降。面對上述不利因素,公司已加快各業務板塊調整,搭建完善的營銷組織結構,建立與大型醫藥商業企業的合作關係,改革成果已在下半年逐步顯現,但預告期間產品的整體銷量較同期仍有下降,淨利潤較同期減少。

上年同期,公司非經營性損益項目合計發生1.02億元,2019年度非經營性損益項目較上年同期預計減少1500萬元,減少的主要原因:上年同期確認無法支付應付款項轉入產生的收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account